July 1 (Reuters) - Recce Pharmaceuticals Ltd (RCE) :
- RECCE PHARMACEUTICALS REPORTS POSITIVE DATA FROM PHASE I/II URINARY TRACT INFECTION (UTI) / UROSEPSIS RAPID INFUSION TRIAL OF RECCE® 327
- RECCE PHARMACEUTICALS LTD: NO SERIOUS ADVERSE EVENTS AND CLINICALLY SIGNIFICANT CHANGES OBSERVED, REINFORCING SAFETY PROFILE OF R327
- RECCE PHARMACEUTICALS LTD: ON TRACK TO INITIATE PHASE II TRIAL OF R327 IN PATIENTS WITH URINARY TRACT INFECTIONS IN H2 2024
News: RCE Recce Pharmaceuticals Says No Serious Adverse Events And Clinically Significant Changes...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
-0.010(2.90%) |
Mkt cap ! $96.87M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 34.5¢ | 33.5¢ | $7.822K | 22.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 9482 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 77675 | 1 |
View Market Depth
| Last trade - 15.47pm 21/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |